Edward Kim, MD, MBA, City of Hope National Medical Center

Edward S. Kim, MD, MBA, discusses the clinical implications of antibody-drug conjugates in HER2-positive solid tumors.

The discussion about the evolution of precision medicine in non–small cell lung cancer (NSCLC) ends as each expert discusses their final thoughts.

Oncology experts provide insight on screening methods available and discuss strategies that may address challenges in identification of targetable mutations/tumor profiles in non–small cell lung cancer (NSCLC).

An overview of TKIs in ROS1-rearranged non–small cell lung cancer (NSCLC) and updated trial results that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting.

Experts have a discussion about their preferred treatment approach for newly diagnosed ALK-rearranged non–small cell lung cancer (NSCLC).

A summary of recent data that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for ALK-rearranged non–small cell lung cancer (NSCLC).

An overview of the RET-fusion data updates that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting in non–small cell lung cancer (NSCLC).

An expert in non–small cell lung cancer (NSCLC) provides an overview of recent data presented at the American Society of Clinical Oncology 2021 annual meeting to treat MET exon 14 mutations.

Edward Kim, MD, MBA, summarizes recent data for HER2-mutated in non–small cell lung cancer (NSCLC) presented at the American Society of Clinical Oncology 2021 annual meeting.

Experts share their real-world experiences regarding treatment with sotorasib, a new FDA-approved option for KRAS G12C-mutated non–small cell lung cancer (NSCLC).

An overview of new data presented at the American Society of Clinical Oncology 2021 annual meeting for KRAS G12C-mutated non–small cell lung cancer (NSCLC).

Jacob Sands, MD, reviews data regarding the investigational oral EGFR inhibitor DZD9008 that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for the treatment of non–small cell lung cancer (NSCLC).

Experts provide an overview of treatment options for exon 20 insertion EGFR mutations in non–small cell lung cancer (NSCLC) and trial updates presented at the American Society of Clinical Oncology 2021 annual meeting .

An expert in non–small cell lung cancer (NSCLC) provides an overview of recent data presented at the American Society of Clinical Oncology 2021 annual meeting to treat MET exon 14 mutations.

Edward Kim, MD, MBA, summarizes recent data for HER2-mutated in non–small cell lung cancer (NSCLC) presented at the American Society of Clinical Oncology 2021 annual meeting.

Edward Kim, MD, briefly summarizes results from the FLAURA trial in the treatment of previously untreated EGFR+ advanced non–small cell lung cancer (NSCLC).

Melissa Johnson, MD, provides an overview of other first generation TKIs for the treatment of non–small cell lung cancer (NSCLC) in the adjuvant setting.

Experts discuss how results from the ADAURA trial may influence treatment decisions in the adjuvant setting of non–small cell lung cancer (NSCLC).

Ben Levy, MD, leads a discussion about the evolution of precision medicine in non–small cell lung cancer (NSCLC) beginning with an overview of the results from the ADAURA trial.